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ABSTRACT 
Background: Isolated thrombocytopenia is  common manifestation f hepa- 
titis C virus (HCV) infection. There is no established treatment modality for this 
condition. The efficacy of standard interferon 0FN) monotherapy has been re- 
ported in some studies. The major disadvantage of this treatment is the high 
rate of recurrence due to viral breakthrough during the first 12 weeks of treat- 
ment. Pegylated IFNs are now the standard regimen for chronic hepatic disease 
due to HCV infection. However, due to a lack of evidence, pegylated IFNs are not 
widely used for HCV-related isolated thrombocytopenia. 
Objective: The aim of this report was to present he case of a male patient 
with severe symptomatic thrombocytopenia due to HCV infection. 
Methods: Thrombocytopenia w s treated with pegylated IFN plus ribavirin. 
Results: Although standard IFN monotherapy failed to achieve virologic and 
hematologic improvement, herapy with pegylated IFN alfa-2a plus ribavirin 
was associated with both virologic and hematologic mprovement without any 
significant adverse ffects. 
Conclusions: Pegylated IFN plus ribavirin was effective in this patient for the 
treatment ofHCV-related thrombocytopenia. However, further esearch is need- 
ed to define the response rate in different patient populations. (Curr Ther Res 
Clin Exp. 2005;66:247-253) Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Extrahepatic manifestations of hepatitis C virus (HCV) infection are observed in 
-38% to 50% of cases~; one of these manifestations is mild to moderate throm- 
bocytopenia. Hepatic disease or cirrhosis with portal hypertension commonly 
leads to hypersplenism-related hrombocytopenia. Nonetheless, thrombocyto- 
penia is more severe in HCV infections than in other hepatic diseases, possibly 
because of increased autoimmunity related to HCV infection. In HCV-related 
thrombocytopenia and idiopathic thrombocytopenic purpura (ITP), large 
thrombocytes are seen on peripheral smears, and a normal or elevated mega- 
karyocyte count is seen in bone marrow aspirates, indicating peripheral de- 
struction of thrombocytes. 
Interferons (IFNs) are used in clinical practice for the treatment of HCV infec- 
tion. 1 Standard IFN monotherapy has been reported in some studies. 1Although 
the main effect of IFNs on HCV is the suppression of replication, 1 other beneficial 
effects include immunomodulation of the host immune system. However, the 
major disadvantage of this treatment is the high rate of recurrence due to viral 
breakthrough during the first 12 weeks of treatment. 2 In addition, few studies 
have reported improvement in HCV-related thrombocytopenia with IFN therapy, 3 
and current guidelines 4 do not mention the treatment of HCV-related thrombo- 
cytopenia with IFNs. Pegylated IFNs are now the standard regimen for chronic 
hepatic disease due to HCV infection. However, due to a lack of evidence, pegy- 
lated IFNs are not widely used for HCV-related isolated thrombocytopenia. 
Herein we report a case of HCV-related severe thrombocytopenia treated with 
IFN alfa-2a, with a fluctuating response. The patient provided written consent o 
use this material for publication. 
CASE PRESENTATION 
An 18-year-old man was admitted to Gazi University, Ankara, Turkey, for treat- 
ment of epistaxis. He had no history of alcohol consumption, use of medica- 
tions or herbal remedies, or drug abuse. Physical examination, including vital 
signs, was unremarkable. Complete blood count revealed severe thrombocy- 
topenia (10,000 cells/mL), and blood chemistry showed mildly elevated hepatic 
enzyme levels (alanine aminotransferase [ALT], 65 IU/mL; aspartate amino- 
transferase [AST], 56 IU/mL [normal range for both, 0--40 IU/mL]). The remainder 
of the blood chemistry results were normal, as were prothrombin time, activated 
partial thromboplastin time, bleeding time, antinuclear antibody test results, 
anticardiolipin antibodies (immunoglobulin [Ig] M, G, and A), platelet-associated 
antibodies (IgG and IgM), and thyroid function test results. The patient had no 
signs of cirrhosis, including peripheral edema, ascites, spider angiomas, 
gynecomastia, or palmar erythema. Hepatic function tests, including synthetic 
functions (eg, albumin, prothrombin time, activated partial thromboplastin 
time) and excretory functions (eg, total/conjugated bilirubin), were all within 
normal limits. Serologic markers for viral hepatitis and HIV were negative, 
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except for HCV antibody. HCV reverse transcriptase polymerase chain reaction 
was 3 x 106 copies/mL. Genetic analysis revealed genotype lb. Abdominal ultra- 
sonography was unremarkable. Serum cryoglobulin studies were negative, and 
no symptoms of arthralgia or palpable purpura or signs of systemic vasculitis 
suggestive of cryoglobulinemia were present. 
Physical examination revealed no lymphoid enlargement suggestive of malig- 
nant lymphoma. Peripheral blood smear revealed no abnormalities in myeloid 
or lymphoid cell lines. To rule out hereditary and other rare causes of thrombo- 
cytopenia, the bone marrow was aspirated. 4 The aspirate showed a moderate- 
ly elevated megakaryocyte count without any other abnormal cell infiltration, 
which would have been indicative of accelerated platelet destruction. The dif- 
ferential diagnosis included immunologic (drugs, idiopathic) and nonimmuno- 
logic (sepsis, disseminated intravascular coagulation, vasculitides, cardiac prosthe- 
sis) causes. Abnormal vessels, fibrin thrombi (sepsis, disseminated intravascular 
coagulation), and intravascular prostheses can all shorten platelet survival and 
cause nonimmunologic thrombocytopenia. However, the patient had no signs of 
vasculitis or vascular or cardiac prosthesis; serum fibrinogen and fibrin degra- 
dation products were normal. The other pathogenetic mechanism of accelerat- 
ed thrombocytopenia is the immunologic destruction of platelets. The most 
common causes of immunologic thrombocytopenia are viral or bacterial infec- 
tion, drug use (often heparin), and ITP. Patients with immunologic thrombocy- 
topenia typically do not have splenomegaly, although they typically do have an 
elevated bone marrow megakaryocyte count, as did this patient. 
As a result, we diagnosed the patient as having HCV-related thrombocytope- 
nia. We could not perform a hepatic biopsy because of the risk for hemorrhage. 
To suppress HCV replication and improve the thrombocytopenia, treatment 
with IFN alfa-2a 3 million U TIW was started. We did not observe any adverse 
effects related to the IFN therapy. At the first visit (during week 2), a mildly ele- 
vated thrombocyte count (15,000 cells/mL) was noted. At week 4, the thrombo- 
cyte count was markedly increased (to 123,000 cells/mL), and the ALT level was 
normalized. However, at week 12, the platelet count decreased markedly, to 
35,000 cells/mL, ALT level was increased to 56 IU/L, and HCV-RNA level re- 
mained >105 copies/mL. Accordingly, we decided to stop standard IFN treat- 
ment. Although the combination of pegylated IFN plus ribavirin is the standard 
protocol for chronic HCV infection, 3a literature search (key terms: interferon, 
thrombocytopenia, and hepatitis C; years: 1980-2005) revealed that few scientif- 
ic data concerning the treatment of HCV-related thrombocytopenia are avail- 
able. However, because combination therapy, at least theoretically, is more 
effective than IFN therapy in suppressing HCV replication, we decided to start 
combination therapy with pegylated IFN and ribavirin. 
At week 12, the HCV-RNA level decreased to 103 copies/mL, ALT and AST lev- 
els normalized, and the platelet count increased to 120,000 cells/mL. At week 
24, HCV-RNA level was still 103 copies/mL and the platelet count had increased 
to 198,000 cells/mL. At week 48 of combination treatment, HCV-RNA was still 
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<105 copies/mL and the platelet count was 186,000 cells/mL. We stopped the 
treatment at week 48 and monitored the patient at 12-week intervals. 
At the time of this writing, the patient had completed 12 months of follow-up, 
at which time the HCV-RNA levels were <105 copies/mL and platelet counts 
were 176,000, 195,000, 156,000, and 188,000 cells/mL at 3, 6, 9, and 12 months, 
respectively. Although the patient experienced flulike symptoms in the first 
4 weeks of treatment, we did not observe any severe adverse ffects associated 
with combination therapy. Because the patient refused to undergo a hepatic 
biopsy at the end of therapy, histopathologic data were not available. However, 
clinical and laboratory data strongly excluded hepatic cirrhosis and portal 
hypertension. Furthermore, the patient did not show any signs of malignant 
hematologic processes during the follow-up period. 
DISCUSSION 
Thrombocytopenia, a common complication ofHCV infection, has been observed 
in 41% of patients with HCV (worldwide)J ,3HCV-related thrombocytopenia is 
classified as mild or severe. In patients with HCV infection and thrombocytopenia, 
mild thrombocytopenia, defined as a thrombocyte count <150,000 cells/mL, is 
observed in 41% to 50% of HCV-infected patients. Severe thrombocytopenia, 
defined as a count <50,000 cells/mL, is observed in 9% of patients. 3,5 A recent 
epidemiologic study 6indicated a strong association between low platelet count 
and HCV infection but not hepatitis B virus (HBV) infection. In that study of 
1690 patients, thrombocytopenia was found in 10.2% of patients with HCV infec- 
tion, 5.2% of patients coinfected with HBV and HCV, 1.9% of those with HBV 
infection, and 1.3% of control subjects. 6 
In another study, elevated levels of platelet-associated IgG were observed 
more frequently in patients with chronic HCV infection (88.1%) than in patients 
with chronic HBV infection (47.1%) (P < 0.05). 7 In a serial report of HCV-related 
cytopenias, autoimmune hemolytic anemia nd neutropenia were usually relat- 
ed to or associated with other underlying autoimmune phenomena (71% of 
patients). 8 Although these patients responded to steroids, they had a poor sur- 
vival rate. In contrast, patients with HCV-related severe thrombocytopenia had 
a lower prevalence of associated autoimmune diseases (11%) and a poorer re- 
sponse to corticosteroids (55%) but lower mortality (6%), with some patients 
having HIV/HBV coinfections. 
The etiology of HCV-related thrombocytopenia is obscure. Although im- 
munologic mechanisms, uch as antiplatelet antibodies and anticardiolipin 
antibodies, are present in some patients, the clinical significance of these has 
not been validated. 9 A thrombokinetic study revealed a significant, nearly lin- 
ear, delayed splenic accumulation; ormal or low-normal mean platelet life 
span; low-normal recovery; depressed platelet production; and a normal or 
slightly elevated megakaryocyte count in the bone marrow. HCV infection of the 
megakaryocytes has been found in some patientsJ ° Several authors have re- 
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ported the presence of HCV-RNA in peripheral platelets, suggesting direct 
infection of the platelets as the cause of increased estruction. 5,u-17 However, 
HCV genotypes have no effect on the severity of thrombocytopenia, u These 
data appear to rule out immunologic mechanisms. 
Another possible factor in the etiology of thrombocytopenia may be de- 
pressed synthesis of thrombopoietin. Inadequate thrombopoietin production 
may contribute to cirrhotic thrombocytopenia. After hepatic transplantation, 
thrombopoietin production is restored, leading to the resolution of thrombocy- 
topenia. 18 However, this mechanism is related to the severity of hepatic fibrosis, 
and patients with HCV-related thrombocytopenia typically are not cirrhotic. 
Some antibodies may bind to platelet Fc receptor, resulting in the accumu- 
lation of immune complexes on platelets and their subsequent destruction. 
Mixed essential cryoglobulinemia h s been reported in 80% to 90% of patients 
with HCV. 19 The immune response against HCV infection leads to the produc- 
tion of IgM rheumatoid factor, which can bind to HCV-IgG (type 2 cryoglobuline- 
mia). Anticardiolipin antibodies may also bind to platelets, causing platelet 
destruction. In fact, many other autoantibodies have been reported with HCV 
infection. In a recent series, 36% of patients with ITP were HCV positive, and 
platelet-associated Igs (PAIgs) were reported in 75% to 88% of patients with 
HCV. 20 However, 1 study failed to find any correlation between PMgs and throm- 
bocytopenia observed in HCV infection: 21 Sanjo et a122 found a significant nega- 
tive correlation between serum PMg concentration a d splenic volume, suggesting 
that hypersplenism and immune-mediated processes are the predominant 
mechanisms of thrombocytopenia. However, the patient in the present report 
had no circulating PAIgs or splenomegaly. 
The appropriate treatment of patients with HCV-associated thrombocytope- 
nia is an important unresolved problem, particularly because the pathogenesis 
of thrombocytopenia is not well established. The various treatment modalities-- 
including steroids, IV Igs, and splenectomy--have failed to achieve lasting 
responses.2,3, 2  
IFN treatment has been investigated in isolated HCV-related thrombocytope- 
nia in some studies, 2of which have reported sustained improvement of throm- 
bocytopenia, even in the first weeks of treatment, n,13 However, in the present 
case, thrombocytopenia improved in the first 4 weeks but was subsequently 
exacerbated. In addition, viral load failed to decrease by >2 logs. All of these 
aspects indicate a breakthrough of HCV infection at week 12. Actually, standard 
IFNs have a sustained viral response rate of -20%. The best predictor of IFN 
nonresponse is the failure of HCV clearance at week 12. In the present case, ini- 
tial improvement and subsequent relapse of thrombocytopenia might have 
been related to IFN resistance. 
The fluctuation i  platelet count is not a rare phenomenon i  HCV infection, n 
However, the most common scenario is the progression from HCV infection with- 
out thrombocytopenia to HIV with thrombocytopenia. B sed on the literature 
search, the wide range of spontaneous fluctuations in platelet count seen in the 
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present case (from 10,000 to >100,000 cells/mL) has not been reported. We 
believe this is clearly a treatment-related improvement of thrombocytopenia.  
Pegylated IFN is a long-acting standard IFN that has been shown in large tri- 
als to be more effective compared with conventional IFN treatment. 24-26 The 
improved response in the present case might have resulted from the sustained 
suppression of HCV replication by pegylated IFN plus ribavirin combination 
therapy. 
CONCLUSIONS 
In this case report, combination treatment with pegylated IFN plus ribavirin was 
effective in the treatment of HCV-related thrombocytopenia.  However, further 
research is needed to define the response rate in different patient populations. 
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